Who are Cyclobenzaprine with caffeine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cyclobenzaprine-with-caffeine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Cyclobenzaprine with caffeine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cyclobenzaprine with caffeine (Cyclobenzaprine with caffeine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Skeletal muscle relaxant with CNS stimulant. Area: Neurology / Pain Management.

phase 3 Skeletal muscle relaxant with CNS stimulant Alpha-2 adrenergic receptors (cyclobenzaprine); adenosine receptors (caffeine) Neurology / Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Cyclobenzaprine with caffeine (Cyclobenzaprine with caffeine) — EMS. Cyclobenzaprine is a muscle relaxant that reduces muscle tension through central nervous system depression, while caffeine is a stimulant that counteracts sedation and enhances alertness.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cyclobenzaprine with caffeine TARGET	Cyclobenzaprine with caffeine	EMS	phase 3	Skeletal muscle relaxant with CNS stimulant	Alpha-2 adrenergic receptors (cyclobenzaprine); adenosine receptors (caffeine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Skeletal muscle relaxant with CNS stimulant class)

EMS · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cyclobenzaprine with caffeine — Competitive Intelligence Brief. https://druglandscape.com/ci/cyclobenzaprine-with-caffeine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab